Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSLV-132 in Systemic Lupus Erythematosus
NCT02194400Phase 1Completed
- Sponsor
- Resolve Therapeutics
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Placebo with RSLV-132 (2 arms). Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 30 days. Started Jul 2014; status: completed.
02
Drugs
RSLV-132
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02194400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194400.